News & Views | Published:

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

Nature Neuroscience volume 20, pages 497499 (2017) | Download Citation

Nusinersen (Spinraza) is a recently approved drug for treating spinal muscular atrophy. Approval of nusinersen may signal new opportunities for using antisense oligonucleotides as treatments for devastating neurological diseases.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Lancet 388, 3017–3026 (2016).

  2. 2.

    US Food & Drug Administration. Spinraza (nusinersen) injection. (2016).

  3. 3.

    , , & Nat. Rev. Neurol. 11, 351–359 (2015).

  4. 4.

    & Nat. Genet. 30, 377–384 (2002).

  5. 5.

    & Nucleic Acids Res. 44, 6549–6563 (2016).

  6. 6.

    & J. Biol. Chem. 276, 45476–45483 (2001).

  7. 7.

    , , , & PLoS Biol. 5, e73 (2007).

  8. 8.

    et al. Sci. Transl. Med. 3, 72ra18 (2011).

  9. 9.

    et al. Neurology 86, 890–897 (2016).

  10. 10.

    US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy. (2016).

  11. 11.

    Nat. Rev. Drug Discov. (in the press).

  12. 12.

    et al. Sci. Transl. Med. (2017).

Download references

Author information

Affiliations

  1. David R. Corey is in the Departments of Pharmacology and Biochemistry, UT Southwestern, Dallas, Texas, USA.

    • David R Corey

Authors

  1. Search for David R Corey in:

Competing interests

D.R.C. receives licensing income from Ionis Pharmaceuticals for an unrelated discovery.

Corresponding author

Correspondence to David R Corey.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nn.4508

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing